Pagibaximab
From Wikipedia, the free encyclopedia
|
Pagibaximab?
|
|
| Therapeutic monoclonal antibody | |
| Source | Chimeric |
| Target | ? |
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | ? |
| Chemical data | |
| Formula | C6462H9996N1728O2028S54 |
| Mol. mass | ? |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Pagibaximab is a chimeric monoclonal antibody and which it is used to treat bacterial infections.
 |
This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it. |
|
|||||||||||||||||
